PMID: 7016401Jan 1, 1981Paper

Impaired lipoprotein lipase activation by uraemic and post-transplant sera

Clinical Science
G A CrawfordJ H Stewart

Abstract

1. Lipoprotein lipase was separated from normal human post-heparin plasma by affinity chromatography and assayed with a 14C-labelled triolein emulsion. No enzyme activity was detected unless whole serum was included in the assay as a source of cofactor, apolipoprotein C-II. 2. After a 10 h fast, serum obtained from 46 normal subjects, eight patients with hypertriglyceridaemia but normal renal function, patients with chronic renal failure (24 undialysed, 20 haemodialysed) and 14 recipients of renal allografts, was added to incubation medium for the assay of lipoprotein lipase to determine the maximum activation of the enzyme. 3. When serum was obtained from normal subjects, maximum activation of the enzyme correlated positively with the concentration of triacylglycerol in the sample. Neither sex nor age had a significant effect on the maximum activation achieved by serum from control subjects. 4. The maximum lipoprotein lipase-activating capacity of serum from uraemic and transplant patients was significantly reduced when compared with serum from healthy controls or from the non-uraemic hypertriglyceridaemic patients. 5. Maximum enzyme activation correlated positively with high-density lipoprotein cholesterol in serum from undia...Continue Reading

Citations

Mar 1, 1997·Kidney International·N D Vaziri, K Liang
Jul 5, 2002·The Journal of Biological Chemistry·Tetsuya ShimizugawaHidehiko Furukawa
Jun 15, 1984·Klinische Wochenschrift·C BreierH Braunsteiner
Feb 1, 1997·Scandinavian Journal of Clinical and Laboratory Investigation·M Arnadóttir
Jan 1, 1997·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·P LeeJ Best

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.